Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer.

Ming Huang Chen*, Peter Mu Hsin Chang, Po Min Chen, Cheng Hwai Tzeng, Pen Yuan Chu, Shyue Yih Chang, Muh Hwa Yang

*此作品的通信作者

研究成果: Article同行評審

49 引文 斯高帕斯(Scopus)

摘要

BACKGROUND: The purpose of this retrospective study was to test whether the pretreatment hematologic profile can predict the prognosis of patients with head and neck cancer. METHODS: Medical records from 278 patients with head and neck cancer were reviewed, and 270 cases were evaluable. Clinical data including age, gender, stage, pretreatment hematologic profile (including white blood cell, platelet, and differential counts, and hemoglobin level) were recorded. Statistical analyses were performed to determine the prognostic effect of these hematologic indicators, as well as clinical variables. The association between the hematologic indicators and clinical factors was also analyzed. RESULTS: Pretreatment monocytes >1,000 cells/microl (P = 0.028), hemoglobin <11.0 g/dl (P = 0.022), and platelet count >400 x 10(3) cells/microl (P = 0.017) were identified as independent prognostic factors in addition to the nodal status and metastasis. A significant correlation between T-stage/monocyte or platelet count and metastasis/platelet count were shown. Monocytosis, anemia, and thrombocytosis were demonstrated to have a cumulative effect on the prognosis of head and neck cancer patients (normal vs. abnormality in one lineage, P = 0.001; abnormality in one vs. more than one lineage, P = 0.005). CONCLUSIONS: A pretreatment hematologic profile can be considered as a useful prognostic marker in patients with head and neck cancer.

原文English
頁(從 - 到)1783-1790
頁數8
期刊Journal of Cancer Research and Clinical Oncology
135
發行號12
DOIs
出版狀態Published - 12月 2009

指紋

深入研究「Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer.」主題。共同形成了獨特的指紋。

引用此